Ordenar por
Immunology and Microbiology
Human Immunodeficiency Virus 1
100%
Human Immunodeficiency Virus
94%
Viral Load
52%
Human Immunodeficiency Virus 2
35%
Drug Resistance
30%
Blood Plasma
27%
Antibody Response
20%
Viremia
19%
Prevalence
17%
T-Helper Cell
17%
Integrase
16%
Virus
14%
Reverse Transcriptase
12%
Next Generation Sequencing
10%
Kidney Transplantation
10%
Antibodies
10%
CD4
9%
Codon
9%
Dynamics
7%
T Cell Depletion
6%
Human Immunodeficiency Virus Type 1 Subtype B
6%
CD4 Lymphocyte Count
6%
Cytotoxic T-Cell
6%
Viral Replication
6%
Enzyme-Linked Immunosorbent Assay
5%
Cell Activation
5%
T Cell
5%
Peripheral Blood Mononuclear Cell
5%
Neutralizing Antibody
5%
Molecular Evolution
5%
Severe Acute Respiratory Syndrome Coronavirus 2
5%
Coinfection
5%
Telomere Length
5%
NS5B
5%
HIV Type 1
5%
Myeloid Dendritic Cell
5%
NS5A
5%
Human Immunodeficiency Virus Type 1 Subtype C
5%
JC Virus
5%
Torque Teno Virus 1
5%
Virus Isolation
5%
Spike
5%
Glycoprotein
5%
Regulatory T Cell
5%
BK Virus
5%
Hepatitis C Virus Genotype 1
5%
Humoral Immunity
5%
Maturation
5%
Medicine and Dentistry
Human Immunodeficiency Virus
84%
Drug Resistance
54%
Resistance Mutation
19%
Integrase
15%
Antiretroviral Therapy
15%
Nonnucleoside Reverse Transcriptase Inhibitor
15%
Human Immunodeficiency Virus 2
15%
Reverse-Transcriptase Inhibitor
12%
Infection
12%
Kidney Graft
11%
Prevalence
10%
Next Generation Sequencing
10%
Human Immunodeficiency Virus 1
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Antibody Response
10%
Rilpivirine
10%
Viremia
7%
Dolutegravir
6%
Proteinase Inhibitor
5%
COVID-19
5%
Cohort Analysis
5%
Tenofovir
5%
Molecular Epidemiology
5%
Virus Isolation
5%
Human Immunodeficiency Virus 2 Infection
5%
Tenofovir Alafenamide
5%
Primary Isolate
5%
Integrase Inhibitor
5%
BK Virus
5%
Nevirapine
5%
T Cell
5%
Cytotoxic T-Cell
5%
Drug Exposure
5%
Health Care Cost
5%
Receptor
5%
Fostemsavir
5%
In Vitro
5%
Messenger RNA
5%
Efavirenz
5%
JC Virus
5%
Antiviral Drug
5%
Tenofovir Disoproxil
5%
Atazanavir
5%
Hepatitis B Virus
5%
Torque Teno Virus 1
5%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
80%
Drug Resistance
50%
RNA Directed DNA Polymerase Inhibitor
25%
Integrase
24%
Nonnucleoside Reverse Transcriptase Inhibitor
19%
Prevalence
19%
Dolutegravir
19%
Rilpivirine
15%
Integrase Inhibitor
12%
Nevirapine
10%
Human Immunodeficiency Virus 1
10%
Human Immunodeficiency Virus 2
10%
RNA Directed DNA Polymerase
9%
Raltegravir
8%
Proteinase
7%
Cabotegravir
7%
Lamivudine
6%
Tenofovir
6%
Infection
6%
Proteinase Inhibitor
6%
Tenofovir Alafenamide
5%
HIV Drug Resistance
5%
Zidovudine
5%
Hepatitis B Virus
5%
Stavudine
5%
Cohort Study
5%
Efavirenz
5%
Antiviral Drug
5%
Tenofovir Disoproxil
5%
SARS Coronavirus
5%
Atazanavir
5%
